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DOI 10.1186/s13058-015-0532-0RESEARCH ARTICLE Open AccessIntegrative analyses identify modulators of
response to neoadjuvant aromatase inhibitors in
patients with early breast cancer
Elena López-Knowles1,2†, Paul M Wilkerson2†, Ricardo Ribas2, Helen Anderson1,2, Alan Mackay2, Zara Ghazoui1,2,4,
Aradhana Rani2, Peter Osin1, Ash Nerurkar1, Lorna Renshaw3, Alexey Larionov3,5, William R Miller3, J Michael Dixon3,
Jorge S Reis-Filho2,6, Anita K Dunbier1,2,7, Lesley-Ann Martin2 and Mitch Dowsett1,2*Abstract
Introduction: Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer
treatment. De novo and acquired resistance, however, is common. The aims of this study were to relate patterns of
copy number aberrations to molecular and proliferative response to AIs, to study differences in the patterns of copy
number aberrations between breast cancer samples pre- and post-AI neoadjuvant therapy, and to identify putative
biomarkers for resistance to neoadjuvant AI therapy using an integrative analysis approach.
Methods: Samples from 84 patients derived from two neoadjuvant AI therapy trials were subjected to copy number
profiling by microarray-based comparative genomic hybridisation (aCGH, n = 84), gene expression profiling (n = 47),
matched pre- and post-AI aCGH (n = 19 pairs) and Ki67-based AI-response analysis (n = 39).
Results: Integrative analysis of these datasets identified a set of nine genes that, when amplified, were associated with
a poor response to AIs, and were significantly overexpressed when amplified, including CHKA, LRP5 and SAPS3.
Functional validation in vitro, using cell lines with and without amplification of these genes (SUM44, MDA-MB134-VI,
T47D and MCF7) and a model of acquired AI-resistance (MCF7-LTED) identified CHKA as a gene that when amplified
modulates estrogen receptor (ER)-driven proliferation, ER/estrogen response element (ERE) transactivation, expression
of ER-regulated genes and phosphorylation of V-AKT murine thymoma viral oncogene homolog 1 (AKT1).
Conclusions: These data provide a rationale for investigation of the role of CHKA in further models of de novo and
acquired resistance to AIs, and provide proof of concept that integrative genomic analyses can identify biologically
relevant modulators of AI response.Introduction
Aromatase inhibitors (AIs), such as anastrozole or letro-
zole, block the synthesis of estrogen [1]. AIs are the
standard of care for the treatment of estrogen receptor
(ER)-positive breast cancer in postmenopausal women
[2]. Estrogen deprivation has a rapid effect on transcrip-
tional profiles, with substantial gene expression changes
identified after 15 days of treatment [3,4]. The most fre-
quently upregulated pathways are those associated with* Correspondence: Mitch.dowsett@icr.ac.uk
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article, unless otherwise stated.focal adhesion, actin cytoskeleton and inflammation,
while the most frequently downregulated pathways are
those related to proliferation, growth and ER transcrip-
tion [5].
Acquired or de novo resistance to AIs is common [6],
and multiple putative mechanisms of resistance to AI
therapy have been proposed. These include intrinsic re-
sistance of tumors to estrogen, aromatase-independent es-
trogenic hormones, signal transduction by non-endocrine
pathways and selection of hormone-insensitive clones
during AI therapy (reviewed by Miller et al. [7]). A num-
ber of potential biomarkers of resistance have been sug-
gested, including overexpression of human epidermal
growth factor receptor-2 (HER2), Cyclin E1, hypoxia-Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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protein kinase (MAPK) [8]. These biomarkers, however,
still require validation in independent cohorts [7] or are
unlikely to account for resistance to AIs in the majority of
tumors [9]. The identification of robust predictive bio-
markers for resistance or sensitivity to AIs is therefore a
research priority.
The observed changes in transcription following treat-
ment with AIs led to the identification of gene expres-
sion signatures in pre-treatment tumor samples reported
to be predictive of response to AIs, as measured by a de-
crease in tumor volume [6,10]. To our knowledge, nei-
ther of these signatures has been validated in a larger
independent cohort. The challenges of translating pre-
dictive gene expression signatures into clinically useful
tools are now well-recognized [11]. These include, but
are not limited to, the facts that 1) resistance to a given
agent may be mediated through multiple distinct path-
ways in different tumors, 2) the low sensitivity of micro-
array platforms for low-level changes in expression or
for changes in non-modal clones may not detect the
mechanism, and 3) resistance to an agent may not mani-
fest in transcriptomic changes, but may be mediated
through mutations or epigenetic aberrations that do not
result in overt transcriptomic changes.
Gene amplification is a common mechanism of onco-
gene activation in cancer [12]. There are multiple reports
describing the association between specific gene amplifica-
tions and resistance to various anti-cancer therapies. For
example, in breast cancer, resistance to tamoxifen is asso-
ciated with FGFR1 amplification [13], while amplification
of CCNE1 [14] and IGF-1R [15] are associated with resist-
ance to trastuzumab. Further examples abound in other
tumor types, such as the association of ERBB2 [16] and
CRKL [17] amplification with resistance to anti-epidermal
growth factor receptor (EGFR) targeted agents in non
small-cell lung cancer and YAP amplification with resist-
ance to doxorubicin in hepatocellular carcinoma [18].
Alternative approaches to identifying biomarkers of re-
sistance to therapy include the use of genome-wide copy
number profiling microarrays to compare the patterns of
copy number aberrations (CNAs) between responders and
non-responders. This approach has identified genomic
loci associated with response to various chemotherapeutic
agents in ovarian carcinoma [19], large B-cell lymphoma
[20] and colorectal carcinoma [21], to name but a few.
Amplified regions frequently encompass multiple genes
and not all genes within an amplicon are overexpressed
and of functional significance [22].
By integrating genome-wide copy number profiling
data and gene expression data, lists of genes associated
with response to specific therapies can be enriched for
biologically relevant targets (for example, the identifica-
tion of FGFR1 amplification as a modulator of tamoxifenresponse [13]). More recently, publication of the Cancer
Cell Line Encyclopedia [23] and the Genomics of drug
sensitivity [24] datasets has demonstrated the power of
integrative genomic and functional genomic approaches
in identifying determinants of response to targeted ther-
apies. To date, there are limited genome-wide data iden-
tifying CNAs that are associated with response to AI
therapy measured by Ki67 as an intermediate endpoint.
Ellis et al. [25] compared whole-genome analysis in
resistant versus sensitive tumors, using Ki67 at surgery
as the index of response; however, the study focused on
mutational background and somatic structural variations
and not specific copy number and expression changes.
The aims of this study were to 1) relate patterns of copy
number aberrations to molecular and proliferative re-
sponse to endocrine treatment, 2) study differences in the
patterns of copy number aberrations between breast can-
cer samples pre- and post-AI neoadjuvant therapy, and 3)
identify putative biomarkers for resistance to neoadjuvant
AI therapy using an integrative analysis approach.
Materials and methods
Patients and samples
To identify molecular determinants of response to AIs,
primary breast cancer samples were retrieved from a
clinical trial and a clinical study in which core biopsies
were taken before and after commencing neoadjuvant
AIs; these were the FAIMoS (ZD1839IL/0223) study
[26], and the Edinburgh study [6].
FAIMoS is a study of those tumors treated with ana-
strozole alone in a phase II placebo-controlled trial that
compared neoadjuvant anastrozole with or without gefi-
tinib in early breast cancer. Postmenopausal women with
stage I to IIB ER-positive and/or progesterone receptor
(PR)-positive non-metastatic breast cancer were eligible.
All patients received neoadjuvant anastrozole for
16 weeks until surgery. Core-cut biopsies were taken at
baseline, after 2 weeks on treatment, and after 16 weeks.
Changes in the Ki67 labeling index were assessed by
performing immunohistochemistry with the MIB1 anti-
body (DakoCytomation, Denmark) and used as the pri-
mary response variable. Ki67 was scored as a percentage
of positive cells in 10 high-power fields chosen to repre-
sent the overall staining across the section. Sufficient
material was available from 51 patients for this study,
none of whom belonged to the gefitinib arm of the trial
(Additional file 1: Figure S1). A reduction in Ki67 of
more than 50% after 2 weeks of anastrozole was used to
identify responders, as previously described [27]. The
study received approval from an institutional review
board at each site and written informed consent was
obtained from each patient before participation.
The Edinburgh study prospectively recruited patients
to receive neoadjuvant letrozole for 3 months, with
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samples from 52 patients were accrued from Edinburgh
ECMC tissue bank but sufficient material was available
from 33 patients. Paired biopsy samples before and after
3 months of letrozole were available for 19 of these pa-
tients (Additional file 1: Figure S1). Clinicopathological in-
formation for samples utilized in this study are shown in
Additional file 2: Table S1. All patients provided informed
consent and sample collection was approved by the local
research ethics committee (Lothian Research Ethics
Committee: 2001/8/80 and 2001/8/81). Both studies were
conducted in accordance with the 1964 Declaration of
Helsinki and International Conference on Harmonization/
Good Clinical Practice guidelines.
Cell lines
MDA-MB134-VI, MCF7, and T47D were purchased from
ATCC (LGC Standards, Teddington, UK), while SUM44
was purchased from Asterand (Royston, UK). Cells were
cultured at 37°C in a 5% CO2 atmosphere in phenol-free
RPMI medium (MDA-MB134-VI and T47D) or DMEM
(MCF7 and T47D) supplemented with 10% fetal bovine
serum and 1nM 17β-estradiol (E2). Prior to experimenta-
tion, cell lines were stripped of estrogen by culturing for
24 hours in their appropriate medium containing 10%
dextran charcoal-stripped fetal bovine serum (DCC) as
previously described [28]. The generation of the long-term
estrogen deprived (LTED) cell line derivative of MCF7 has
been previously described [29]. All cell lines were shown
to be mycoplasma-free and authenticated by means of
short tandem repeat analysis (PowerPlex® 1.2 System,
Promega, Fitchburg, WI, USA).
Nucleic acid extraction
Tumor samples from FAIMoS and Edinburgh were mi-
crodissected under a stereomicroscope (Olympus SZ61,
Tokyo, Japan) using a sterile needle to ensure a tumor
cell content >90% as previously described [30]. DNA
extraction was performed by proteinase K digestion and
phenol-chloroform precipitation. Total RNA from FAIMoS
samples was extracted from un-microdissected sections
using the RNeasy kit (Qiagen, Hamburg, Germany) as
previously described [31]. RNA purity and integrity was
assessed using the Agilent Bioanalyzer (Santa Clara, CA,
USA), with samples only being analyzed if RNA integrity
scores were >5.0. Sample processing and RNA extraction
from samples of the Edinburgh cohort has been previously
described [6]. For cell lines, DNA was extracted using the
DNeasy blood and tissue kit (Qiagen) and RNA was
extracted using the RNeasy kit (Qiagen).
Microarray comparative genomic hybridization (aCGH)
Fifty one FAIMoS and 33 Edinburgh patients had sufficient
good-quality DNA to run aCGH. The aCGH platform usedfor this study comprises approximately 32,000 bacterial arti-
ficial chromosome (BAC) clones tiled across the genome,
which has been shown to be as robust as, and to have com-
parable resolution with high-density oligonucleotide arrays
[32,33]. DNA labeling, array hybridization, and image acqui-
sition were performed as previously described [34]. aCGH
data were pre-processed and analyzed using the Base.R
script in R version 2.9.0 as previously described [35]. A de-
tailed description of aCGH analysis methods is provided in
the Additional file 2. Microarray data is available in Array
Express [36].
Gene expression profiling
RNA of sufficient quantity and quality was available from
47 of the baseline samples from the FAIMoS cohort. RNA
amplification, labeling, and hybridization on HumanWG-6
v2 Expression BeadChips (Illumina, San Diego, CA, USA)
were performed according to the manufacturer's instruc-
tions at a single Illumina BeadStation facility [37]. The
Expression BeadChips cover more than 48,000 transcript
probes and their annotation is publicly available. Gene
expression probes were mapped to ensemble genes using
ensembl build 37 assembly 55. Matched copy-number
states were assigned to gene expression probes based upon
the median of all BAC probes overlapping the genomic po-
sitions of each corresponding ensembl gene. The integra-
tive analysis overlapping the aCGH and expression data is
described in detail in Additional file 2. Microarray data
have been deposited in the Sagebase [5,38].
Proliferation assays
To assess the effect of silencing of CHKA, SAPS3 or LRP5
on ER-driven proliferation, cells were seeded in DCC
medium and transfected with pools and individual siRNAs
targeting CHKA (M-006704-01 Thermo Scientific, Epsom,
UK), SAPS3 (L-014646-01-0005 Dharmacon, Lafayette,
CO, USA) and LRP5 (L-003844-00-0005 Dharmacon) the
following day using RNAiMAX (Invitrogen, Paisley, UK) or
Dharmafect3 (Dharmacon) according to manufacturers’ in-
structions and as previously described [39]. Non-targeting
control siRNA pools (siControl pool 2, D-001206-14-20
Dharmacon) and a SMARTpool targeting PLK1 (M-
003290-01 Dharmacon) were used as negative and positive
controls respectively. After 24 hours, cells were treated
with E2 as indicated and cell viability assessed after 6 days
using the Cell Titer-Glo luminescent cell viability assay ac-
cording to manufacturer’s instructions. Cell proliferation was
displayed as fold-change over siControl transfected, DCC-
treated cells. Each experiment consisted of six replicates,
and data presented are representative of at least two bio-
logical replicates in each case. In parallel to each assay,
the same cells were transfected in 24-well plates for RNA
extraction 48 hours post-transfection to confirm target
gene silencing in each assay by quantitative PCR and
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CHKA silencing was validated using a second set of inde-
pendent siRNAs and four shRNAs described in detail in
Additional file 2: Supplementary materials and methods
and Additional file 3: Figure S2.
Immunoblotting
Whole cell lysates and western blotting was performed as
previously described [40] using antibodies (see Additional
file 2: Table S2) diluted in 5% BSA/TBST according to
manufacturer’s recommendations. Incubation with an
horseradish peroxidase (HRP)-conjugated secondary anti-
body was then performed, and protein detected by chemi-
luminescence (Supersignal, Amersham, UK). Protein-band
densitometry was measured with ImageJ software.
Cell flow cytometry
Cells were harvested by scraping and were washed in
PBS. This was followed by fixation by adding ice-cold
70% ethanol and maintaining the cells at 4°C overnight.
The ethanol-fixed cells were centrifuged and resus-
pended in RNase A at 10 mg/mlU/ml and incubated at
room temperature for at least 30 minutes. The cells were
stained in PBS containing 50 μg/ml propidium iodide
(PI) and stored in the dark until analysis. Cell cycle ana-
lysis of 10,000 cells per sample was carried out in a flow
cytometer (LSR II, Becton, Dickinson, San Jose, CA,
USA). The data were analyzed with BD FACSDiva (BD
Biosciences, San Jose, CA, USA).
Quantitative real-time PCR (qRT-PCR)
Reverse transcription was performed with Superscript III
(Invitrogen, UK), using 1 μg total RNA per reaction. qRT-
PCR was carried out using TaqMan® chemistry on the ABI
Prism 7900HT (Life Technologies Ltd, Paisley, UK), and
analyzed using the ΔΔ cycle threshold (ΔΔCt) method in
triplicate, as previously described [41]. Probes for CHKA
(Hs00957875_m1), TFF1 (Hs00907239_m1) and GREB1
(Hs00536409_m1) were purchased from Life Technologies.
The expression level of a housekeeping gene (HKG),
FKBP15 (Hs00391480-m1), was also assessed.
Copy number analysis by qRT-PCR
Copy number in cell line DNA was measured by Taqman
copy number assays as described previously [42]. Twenty
nanograms of DNA were run in quadruplicate for each
cell line. Assays for CHKA (Hs03778879_cn), LRP5
(Hs06321584_cn), SAPS3 (Hs06297988_cn) and reference
gene TERT were purchased from Life Technologies.
ER/ERE transactivation assays
To study the effect of RNAi-induced silencing of CHKA on
ER/ERE transactivation, the activity of a the EREIItkluc re-
porter was assessed following silencing of CHKA in DCCmedia and in the presence of E2, as previously described
[43]. Further details are available in Additional file 2.
Statistical analysis
Statistical analysis was carried out with PRISM v.6.
Spearman correlation was used to compare the propor-
tion of the genome altered and Ki67 levels and aCGH
circular binary segmentation (cbs) ratios and Ki67 change.
The Mann-Whitney U-test and Kruskal-Wallis analysis
were used to compare Ki67 levels and Hicks scores. The
t-test was used to compare the effect of each siRNA to
siControl in DCC conditions and to compare the effect of
siCHKA4 in DCC and 1nM E2 conditions in the transacti-
vation assays. One-way analysis of variance (ANOVA) was
used to analyze the effect of siRNAs and E2 escalating
doses on each cell line and to analyze the effect of
siCHKA on the mRNA levels of TFF1 and GREB1.
Results
The proportion of the genome with copy number
aberrations in ER-positive breast cancer correlates with
Ki67 labeling index at baseline but not with changes in
Ki67 following AI therapy
Ki67 expression is a well-established marker of prolifera-
tion. Short-term change in Ki67 has been validated as an
intermediate endpoint of clinical benefit from AIs [27].
To determine if Ki67-based response to AI is associated
with distinct patterns of copy number aberrations, DNA
samples from 84 ER-positive breast carcinomas from
postmenopausal women were subjected to copy number
profiling using a tiling path 32 K BAC array.
The most common copy number aberrations identified
were gain of 1q23.1-44, 7q11.1-11.21, 8q21.2-q24.13 and
19q11, loss of 1q36.33-p36.12, 11q22.3-q25, 17p13.3-p11.2
and 16q21-q24.3 and amplification at 1q21.3-q44, 8p12-
q24.3.3 and 11q13.2-q13.4 (Figure 1A and Additional file
2: Table S3). Given that all the tumors were ER-positive
and predominantly of low histological grade, the frequent
loss of 16q is in keeping with previous reports [44]. The
most common amplified gene was CCND1 (21%).
The proportion of the genome with copy number aber-
rations (proportion of the genome altered) was calculated
for each case at baseline and utilized as an index of gen-
omic instability. This was significantly correlated with
Ki67 baseline levels (Spearman r = 0.414, P = 0.0038,
Figure 1B, left panel), consistent with the notion that
highly proliferative tumors accumulate copy number aber-
rations at a more rapid rate. This correlation was not due
to grade (one-way ANOVA, P = 0.58). Furthermore, a sig-
nificant correlation was not identified when comparing
the proportion of the genome altered with Ki67 2-week
decrease percentages (Figure 1B, right panel).
The patterns of copy number aberrations in each case
were classified using the genomic pattern classification
Figure 1 Correlation of the proportion of the genome with copy number aberrations and the patterns of copy number aberrations
with Ki67 indices of proliferation and response to aromatase inhibitors. (A) A frequency plot of gains and losses (top panel) or amplifications
(bottom panel) in 84 samples of ER-positive breast carcinomas from post-menopausal women before treatment with anastrozole. The proportion of tumors
in which each bacterial artificial chromosome (BAC) clone is gained/amplified (green bars) or lost (red bars) is plotted (y-axis) for each BAC clone according
to its genomic position (x-axis). (B) Scatter plots showing the correlation between the proportion of the genome with copy number aberrations on
the y-axis and baseline Ki67 expression levels (left side) or the percentage decrease in Ki67 expression levels after 2 weeks of anastrozole (right side).
Spearman correlation demonstrates a statistically significant positive correlation between proportion of the genome altered and baseline Ki67 expression
levels. (C) Dot plots demonstrating the relationship between the distinct patterns of copy number aberrations defined by Hicks et al. and baseline Ki67
expression levels (left side) or the percentage decrease in Ki67 expression levels after 2 weeks of anastrozole (right side).
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plex pattern (broad segments of duplication and deletion
usually entire chromosomes), the sawtooth pattern (nar-
row segments of duplication and deletion more or less
affecting all chromosomes) and the firestorm pattern
(resembling the simplex type but with at least one local-
ized region of amplification within a single chromo-
some). Thirteen tumors were classified as simplex, 23 as
sawtooth and 48 as firestorm. A significant difference in
baseline Ki67 labeling index was identified between cases
with the firestorm pattern and both sawtooth and sim-
plex patterns (Figure 1C, left panel), but not with Ki67
2-week decrease (Figure 1C, right panel).
Pairwise analysis of pre- and post-AI-treated samples
identifies differences in copy number aberrations
following treatment
To determine if treatment with letrozole is associated
with changes in the copy number profiles of ER-positive
breast carcinomas, DNA from 19 matched pairs of pre-
and post-treatment breast carcinoma samples were sub-
jected to copy number profiling as described above. A
grouped analysis was performed to compare the patterns
of copy number aberrations in the pre-treatment sam-
ples with those in the post-treatment samples. Matched
samples largely had similar patterns of copy number ab-
erration (Figure 2A) and clustered together (Figure 2B),
and no copy number aberration was significantly more
frequently present in the pre- or post-AI samples.
Despite these findings, a careful inspection of the heat-
map identified genomic loci affected by copy number
aberrations only in the pre- or post-treatment samples
of 7 out of 19 cases (Figure 2B, green boxes). Given that
the heatmap is constructed from aCGH copy number
states rather than continuous copy number ratios, these
differences could be due to artificial changes in ratios
near the cutoff for defining gains or losses. A detailed
pairwise analysis of the copy number profiles confirmed
that in most cases where differences in gain/loss were
noted, the trend in the copy number aberration was
similar in each sample of a pair, but in one or other, the
threshold for gain or loss was not reached. In two cases,
however, amplicons were identified that were present in
only one of the matched samples from a given patient. In
the first case, amplification at 12q12 was present at base-
line but absent after 3 months of AI therapy while amplifi-
cation at 1q31.1-q41 was apparent only after 3 months of
AI therapy (Figure 2C, top panels). In the second case,
amplification at 1p22.2-p22.1 and 8p11.23-p11.22 was ab-
sent at baseline but present after 3 months of AI therapy,
while amplification at 3q13.11 was present at baseline
and absent after 3 months of AI therapy (Figure 2C, bot-
tom panels). These data demonstrate that while samples
by and large retain similar patterns of copy numberaberrations during AI treatment, there is evidence of
changes in focal copy number aberrations following
treatment with AIs.
Integrative analysis of copy number and gene expression
profiling data with Ki67-based response data identifies
amplified genes associated with a poor response to AI
therapy
To determine which genes were overexpressed when
amplified, an integrative analysis was first performed by
overlaying gene expression data with aCGH-derived
copy number data for a subset of 47 patients from which
both datasets were available. In the first instance, to
determine which genes had expression levels that were
copy number-regulated, aCGH data were utilized as a
continuous variable and cbs-smoothed ratios were corre-
lated with microarray-derived gene expression levels.
This approach identified 3,706 genes with expression
levels that were significantly correlated with copy num-
ber (Pearson correlation, adjusted P <0.05, Additional
file 2: Table S4). Next, cbs-smoothed ratios were used to
define copy number states on a gene by gene basis, and
this was used as a grouping variable (that is, amplified ver-
sus non-amplified), while expression levels were used as
the dependent variable, as previously described [35]. This
approach identified 628 genes, which were significantly
overexpressed when amplified (Mann-Whitney U-test
adjusted P <0.05, Additional file 2: Table S5). The two
most strikingly associated regions were at chromosome
11q13.2-q13.4 and 17q12-q21.2 (Figure 3A).
Next, to identify genes with copy numbers associated
with proliferative response to AI therapy, an integrative
analysis of baseline aCGH with Ki67 decrease after 2 weeks
of AI therapy was performed. When aCGH-derived cbs-
smoothed ratios were correlated with 2-week Ki67 de-
crease using Spearman’s correlation, 48 genomic loci
harboring a significant association with 2 week Ki67
decrease were identified. Forty-one regions positively
associated (Additional file 2: Table S6A) and seven regions
negatively associated (Additional file 2: Table S6B) to
which a total of 734 genes mapped.
By combining the analyses above, a set of nine genes was
identified that, when amplified, were associated with a poor
proliferative response to AI therapy (defined as a <50%
reduction in Ki67 labeling index after 2 weeks of AI
therapy) and that were significantly overexpressed when
amplified (Figure 3B). These genes were clustered at
11q13.2 (NDUFS8, CHKA, SUV420H1, LRP5 and SAPS3),
17q21.32 (CALCOCO2, UBE2Z, and SNF8), 17q21.33
(~1.5Mbp distal to the cluster at 17q21.32, encompassing
PHB, EPN3, and SPATA20) and 11p15.3 (ZBED5).
It is plausible that amplification of one or more of
these genes could potentially constitute a negative pre-
dictive biomarker for AIs. To test this hypothesis, a well-
Figure 2 (See legend on next page.)
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Figure 2 Grouped and pairwise analysis of matched pre- and post-aromatase inhibitor (AI) therapy copy number profiles. (A) Frequency
plot of copy-number gains and losses (top) or amplifications (bottom) in 19 matched pre- and post-letrozole-treated breast cancer samples.
The proportion of tumors in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted (y-axis)
for each BAC clone according to its genomic position (x-axis). No significant differences were identified between the two components. (B)
Hierarchical cluster analysis performed with array comparative genomic hybridization (aCGH) categorical states (that is, gains, losses and
amplifications) using the Euclidean distance metric and Ward's algorithm of 19 matched pre- and post-letrozole treatment samples from estrogen
receptor (ER)-positive breast carcinomas. Matched samples from each patient preferentially cluster together, and have similar patterns of copy number
aberrations. In some cases, small regions show differential copy number states between matched samples (green squares), but these are private
events. The heatmap displays each case along the x-axis and the genomic position along the y-axis. Amp, amplification; Gain, copy number
gain; Loss, copy number loss; NC, no copy number change. (C) Genome plots of pre- and post-letrozole samples from two patients. The genomic
position is plotted along the x-axis and circular binary segmentation (cbs)-smoothed log2 ratio on the y-axis; amplifications are shown in bright
green, gains in dark green, losses in dark red and normal copy number in black. Red stars denote amplicons present in only one sample of a
matched pair.
López-Knowles et al. Breast Cancer Research  (2015) 17:35 Page 8 of 16studied model of AI-resistance was utilized (the MCF7-
LTED model [29]). Three of the nine genes were upregu-
lated in MCF7-LTED cells compared to MCF7 cells
(CHKA, LRP5 and SAPS3). These genes that are overex-
pressed when amplified and are associated with a poor
proliferative response to AI therapy (Figure 3C) were
taken forward for functional validation.Functional validation identifies CHKA as a potential
modulator of ER-driven proliferation
The effect of silencing of each of CHKA, SAPS3 and
LRP5, was assessed using validated siRNA SMARTpools,
on ER-driven proliferation in a panel of ER-positive breast
cancer cell lines that harbored amplification of CHKA,
LRP5 and SAPS3 (that is, SUM44 and MDA-MB134-VI)
or normal copy number at 11q13-q14 (that is, T47D and
MCF7), as defined by copy number analysis (Additional
file 4: Figure S3A). Of the three genes investigated, only
CHKA appeared to constitute a potential driver, given that
its RNAi-mediated silencing resulted in a consistent re-
duction in cell viability in SUM44 cells, but surprisingly,
had no effect in the MDA-MB134-VI (Figure 4A, B and
C). However, in contrast to SUM44, the MDA-MB134-VI
did not show an increase in CHKA expression, providing
a likely explanation for this discordance (Additional file 4:
Figure S3B).
To address the role of overexpression of CHKA, LRP5
and SAPS3 in AI resistance, in the absence of amplifica-
tion we utilized the MCF7-LTED cell line [29]. siCHKA
had a significant impact on the viability of MCF7 cells,
which lack amplification of the CHKA locus, however, this
was only apparent in the absence of E2. In addition, silen-
cing of CHKA in the MCF7-LTED cell line produced a
significant loss of viability in the absence of E2.
Taken together, these data suggest that in cells harbor-
ing the amplification with concomitant overexpression,
CHKA is required for cell proliferation. Furthermore, the
cellular context may well be important. For instance, in
acquired resistance to estrogen-deprivation, CHKAexpression may be required for the survival of cells that
rely on ligand-independent ER activity, even in the absence
of CHKA gene amplification.Mechanistic investigation of the effect of CHKA on
proliferation
To determine if the effects of CHKA silencing on prolif-
eration may be mediated by ER transcriptional activity,
an ER/ERE reporter assay was performed in the cell line
that demonstrated the most profound effect on prolifer-
ation (that is, SUM44). Following silencing of CHKA,
there was approximately 25% reduction in luciferase ac-
tivity of the ER/ERE reporter construct in the presence
of E2 (Figure 5A, red bars), suggesting that CHKA mod-
ulates ER transactivation. Consistent with these findings,
the expression levels of two genes, previously reported
to be estrogen-regulated (that is, GREB1 and TFF1 [37]),
were reduced following silencing of CHKA (Figure 5B).
Finally, to determine the downstream signaling path-
ways involved in the CHKA-mediated reduction in ER
transactivation, western blotting following CHKA silen-
cing was performed using antibodies to major signaling
pathways known to influence ER activity (that is, p90RSK,
AKT, and S6, Figure 5C). These experiments were per-
formed in a time course to assess the effects of CHKA
silencing during the activation phase of ER signaling
(1 hour treatment with E2) and during the turnover phase
of ER signaling (24 hour treatment with E2). Following si-
lencing of CHKA, a reduction in ER-alpha expression was
noted with a subsequent reduction in phosphorylation at
ERSer167 (apparent only when assessed after 1 hour of
treatment with E2), providing further support for the find-
ing of reduced ER/ERE transcription activity and reduced
expression of key ER-regulated genes. While there was no
appreciable difference noted in the expression of pp90RSK
or pAKTSer473 following CHKA silencing, there was a re-
duction in pAKT Thr308, accompanied with a reduction in
total AKT, which was more apparent in the presence of
E2. We assessed the effect of CHKA ablation on cell-cycle
Figure 3 (See legend on next page.)
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Figure 3 Integrative analysis of microarray-based comparative genomic hybridization, gene expression and Ki67-based response
data. (A) Matched heatmaps of gene expression and aCGH within two amplified loci; 11q13.2-q13.4 and 17q12-q21.1. Bar plots show the
result of a Mann-Whitney U-test for expression as a continuous variable and gene amplification as the grouping variable. Bars in red show
adjusted P-values <0.05. aCGH, green copy number loss; black, no copy number change; dark red, copy number gain; bright red, gene
amplification; gene expression: green, downregulation; red, upregulation; MWU, Mann-Whitney U-test; adjp, adjusted P-value. (B) Venn diagram
shows the intersect between the list of genes that are overexpressed when amplified and those genes that are associated with a poor response
to AI when amplified. The call-out box lists these genes and their loci, highlighting that only three genes are upregulated in long-term
estrogen deprived (LTEDs). (C) Scatter plots demonstrating that for each of the three genes selected for functional validation, significant
negative correlation was identified between the aCGH-derived cbs ratios and the percentage decrease in Ki67 following 2 weeks of AI
therapy. In each plot, cbs-smoothed ratios are plotted on the y-axis while the percentage decrease in Ki67 at 2 weeks is plotted on the
x-axis. Red, CHKA, Blue, LRP5, Green, SAPS3.
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sion of cyclin B1, pRb and cyclin D1 by immunoblotting
(Figure 5C). Silencing of CHKA in both the presence and
absence of E2 resulted in a marked decrease in each of
these proteins. Taken together these data suggest that
CHKA may regulate ER activity through AKT phosphor-
ylation in a p90RSK-independent manner, leading to cell-
cycle progression.
Discussion
In this study, an integrative analysis of copy number
profiling, gene expression microarray and Ki67-based AI
response data was performed using data from samples in
two cohorts of neoadjuvant AI therapy in postmeno-
pausal patients with ER-positive early breast cancer. No
significant differences in the frequency of gene copy-
number aberrations were found when pre- and post-AI
therapy samples were compared. This is to be expected
given that there is evidence for numerous mechanisms
of resistance to AIs many of which would not be ex-
pected to be dependent on gene copy-number changes
[7]. Non-recurrent differences in copy number at spe-
cific loci (that is, 1p11.23-p11.22, 1q31.1-q41, 3q13.11,
8p11.23-p11.22 and 12q12) between samples before and
after 3 months of letrozole therapy were observed in 6
of 19 studied cases (Figure 2B). This observation sug-
gests that the selective pressure applied by AI therapy
may result in the selection of non-modal clones, causing
enrichment or loss of cells harboring specific amplicons,
and that resistance to AIs may constitute a convergent
phenotype [11]. An alternative explanation, however, is
that these differences in gene copy-number profiles may
be merely a manifestation of spatial intra-tumor genetic
heterogeneity. Indeed, this study highlights the need to
interrogate intra-tumor genetic heterogeneity for a full
understanding of the mechanisms of resistance to spe-
cific agents, using combinations that can overcome the
challenges that may be posed by intra-tumor spatial
genetic heterogeneity. All the same it should be noted
that in this study few differences were noted in the
copy number landscape between pre-treatment andon-treatment cores: any confounding degree of genetic
heterogeneity that is dependent on the small amount of
a tumor sampled in cores would have been revealed by
that comparison.
Overlaying gene expression data with copy-number
profiling data identified a set of 628 genes, which are sig-
nificantly overexpressed when amplified, including genes
at two commonly amplified regions (11q13.2-q13.4 and
17q12-q21.2). Nine of these 628 genes were also nega-
tively correlated with the decrease in Ki67 expression
after 2 weeks of AI therapy (a surrogate for response to
AIs). These clinical data are reflective of pre-existing, de
novo mechanisms of resistance. To parallel these obser-
vations we assessed the possible importance of the genes
in a panel of ER+ cell lines, two of which harbored the
amplification and two of which did not. We prioritized
the functional analysis of three of the nine genes based
on differential expression between MCF7 and the LTED
derivative (a model for acquired AI resistance), followed
by functional validation. This pipeline identified CHKA
as a gene that is significantly overexpressed when ampli-
fied, and when amplified is associated with a poor Ki67
response to AI therapy. Mechanistic investigations re-
vealed that CHKA expression modulates ER transcrip-
tional activity via AKT and S6 phosphorylation, but
independently of p90RSK activity, which resulted in a re-
duction in cell-cycle progression markers. Antagonizing
ER signaling has been shown to attenuate cyclin-
dependent kinase (CDK)/cyclin complexes at multiple
levels [46]. Furthermore, ER modulates transcription of
cyclin D1. Hence suppression of ER signaling leads to
inhibition of CDK activity and the maintenance of Rb in
a phosphorylated and active state inhibiting progression
to S-phase.
CHKA is located at 11q13.2 and encodes the protein
choline kinase alpha (CHKA), which catalyses the phos-
phorylation of choline as the first step of the Kennedy
(phospholipid synthesis) pathway [47]. Choline phosphor-
ylation by CHKA has been shown to be upregulated in
many cancer types, including breast, lung, colorectal and
prostate cancer [48]. In our study we identified CHKA
Figure 4 Functional validation of genes identified as potential modulators of aromatase inhibitor (AI) response when amplified and
overexpressed. (A) Western blotting of lysates from SUM44 cells: each of the three genes, silenced and blotted for, was used to demonstrate siRNA
efficacy and antibody specificity. (B) Panel of estrogen receptor (ER)-positive cell lines were used to assess the effect of RNA-interference-induced
silencing of CHKA, LRP5 and SAPS3 on cell viability. Cell line names in red font harbor amplification of these genes; those named in black do not. Data
for each knockdown (performed using SMARTpools) were normalized to readings from cells transfected with a non-targeting control and grown in
dextran charcoal-stripped (DCC) media. Data are representative of six replicates from at least two independent experiments. Numbers indicate
t-test P-value. (C) The same panel was used to assess the effect of RNA-interference-induced silencing of CHKA, LRP5 and SAPS3 on ER-driven
proliferation. After growing and transfecting cell lines in DCC, cell viability was assessed as a surrogate marker of proliferation in the presence of
increasing concentrations of estrogen (E2). Cell line names in red font harbor amplification of these genes; those in black do not. Data for each
knockdown (performed using SMARTpools) were normalized to readings from cells transfected with a non-targeting control and grown in DCC
media. Drug curves were inferred from non-linear regression. Error bars represent standard error of the mean. Data are representative of six replicates
from at least two independent experiments. P-value is for one-way analysis of variance.
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Figure 5 Mechanistic assessment of the effect of CHKA in modulating response to aromatase inhibitor (AI) therapy. (A) Following
RNA-interference-mediated silencing of CHKA, SUM44 cells were transfected with an estrogen receptor (ER)/ERE luciferase reporter construct, and
then treated with E2 or dextran charcoal-stripped media (DCC) for 2 days before reading luciferase activity. Data are normalized to the activity in
the DCC-treated control transfected cell lines. *Significant P-value (<0.05) between the indicated column and corresponding siControl-equivalent.
(B) To validate effects seen with the ER-ERE reporter assay, expression levels of two well known ER-regulated genes (TFF1 and GREB1) were assessed
by quantitative real-time PCR following RNA-interference-induced silencing of CHKA. Data normalized to DCC-treated control transfected cell
lines; *P-value <0.01 between indicated column and corresponding siCON equivalent. (C) Following RNA-interference-induced silencing of
CHKA, cell lysates were subjected to gel electrophoresis and western blotting using indicated antibodies. Cells were treated with 1nM E2 for 1 h
or 24 h following transfection, to represent the two phases of ER dynamics (early active- and late turnover phase). Blots are representative of at
least two independent experiments; numbers below each band represent densitometry analysis of intensity, measured as a ratio of the siControl
with no siCHKA or E2 treatments.
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[49,50]. Amplification at 11q13-q14 is a complex event. It
is currently accepted that at least four cores of independ-
ent amplification are found at this locus [51]. CHKA lies
between the smallest regions of amplification of the first
and second core of the 11q13-q14 amplicon. Curtis et al.
identified a high-risk group of ER-positive luminal tumors
with amplification of 11q13/14 (Int2). This group har-
bors amplification of several genes such as CCND1 and
EMSY and is in close proximity to the region containing
CHKA [49]. In the large METABRIC study of CNV and
gene expression CHKA amplification does not associate
with survival but its overexpression did correlate with
poorer survival. It should be noted, however, that ana-
lyses of survival are generally unhelpful for detectingFigure 6 The effect of siRNA (CHKA) on cell cycle as determined by fl
content in Sum44 WT cells treated with dextran charcoal-stripped media (D
cell cycle phases in the cells treated with DCC. CHKA arrests cells at the G1
DCC + E2. (B) The percentage of cells at each cell phase: G0/G1, S, G2/M ar
performed in triplicate; **P <0.005 and *P <0.01.the impact of response or resistance to a particular
treatment.
Using RNAi-mediated silencing and ERE-reporter tech-
niques, the role of CHKA on ER-driven proliferation was
characterized in this study, highlighting the importance of
functional characterization of genomic and transcriptomic
aberration using appropriate phenotypes as experimental
readouts in multiple models. In this case, for example,
previous studies demonstrated a significant effect of
CHKA silencing on proliferation in MCF7 cells [52].
However, those experiments were performed in complete
growth medium; in the same study, silencing CHKA in
serum-starved MCF7 cells produced no difference in pro-
liferation, and an interaction between CHKA, EGFR and
c-Src was demonstrated and found to be required for theow cytometry. (A) Flow cytometry was used to compare DNA
CC) and DCC + E2. There was no significant difference between the
/S, but not at the G2/M phase of the cell cycle in cells treated with
e shown on the bar chart as the mean ± SD. The experiment was
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MCF7-LTED cell line showed that whilst they do not har-
bor amplification of CHKA the transcript level is signifi-
cantly increased. Furthermore, this cell line shows elevated
levels of both the EGF canonical pathway and c-Src [53].
These data provide further support for the proposed
mechanism of CHKA on ER-driven proliferation proposed
in this study, which warrants further investigation.
This study has a number of limitations. First, it was limited
by relatively small sample size. Although the two trials uti-
lized in the study recruited over 160 suitable patients, only a
subset of these samples were available in sufficient quantity
for use in this study. The use of the neoadjuvant setting with
Ki67 change as its primary endpoint provides substantially
greater statistical power than a similar sized study of adju-
vant therapy: with the former there is a direct readout of a
patient’s response or resistance to treatment, which is not
the case with the latter where patients are free of clinically
detectable disease by which to judge response. It is import-
ant to note that Ki67 has been validated as an intermediate
marker of long-term benefit from endocrine treatment [27]
and, in this respect it is a better endpoint than clinical
response per se. However, differences in methodology for
Ki67 immunohistochemistry and scoring between the two
trials precluded combination of Ki67 response data. Like-
wise, given that different platforms were used for gene ex-
pression profiling in the two trials, this study was limited
to the largest dataset (FAIMoS trial, n = 47) for the integra-
tive copy number and gene expression analysis.
It should be noted that this study aimed to identify genes
that have pathoclinical significance when both amplified
and overexpressed. It is notable that there are reverse asso-
ciations between cyclin-D1 expression with prognosis and
resistance to tamoxifen or anastrozole according to whether
CCND1 is amplified or not (overexpression and amplified,
poor prognosis; overexpression and non-amplified, good
prognosis [54]). Thus the approach taken in this study may
not identify genes that associate with clinical phenotype
only according to their degree of expression.Conclusions
Using a combination of integrative analysis of primary tu-
mors and functional characterization in in vitro models, we
have provided evidence that 1) copy number profiles can
alter in a subset of ER-positive breast cancers in response
to AI treatment, and 2) distinct copy number aberrations
(such as CHKA amplification) can influence the sensitivity
of cancer cells to estrogen deprivation, providing evidence
to suggest that specific copy-number aberrations may result
in resistance to AI therapy. Finally, our study provides a
proof of principle that integrative genomic analyses of pri-
mary tumors may lead to the identification of novel mecha-
nisms of resistance to specific therapeutic agents.Additional files
Additional file 1: Figure S1. Overview of study design with patient
numbers for each analysis used to derive the list of genes for functional
validation.
Additional file 2: Supplementary materials and methods: more
detail of materials and methods, a workflow and lists of genes,
regions and available demographic data. Table S1. Summary of the
available clinicopathological details of the samples included in this study
from each neoadjuvant trial, together with Ki67 data. Table S2. Details of
antibodies used for immunoblotting. Table S3. Recurrent gains, losses (in
>50%) and amplifications (in >2.5%) in 84 estrogen receptor (ER)-positive
breast cancer samples. Table S4. List of 3,706 copy number-regulated
genes derived from a correlation analysis of array comparative genomic
hybridization (aCGH) circular binary segmentation (cbs)-smoothed ratios
with gene expression profiling data from 47 ER-positive breast cancer
samples. Table S5. List of 628 genes that are significantly overexpressed
when amplified, derived from a gene by gene Wilcoxon analysis of
expression data from 47 ER-positive breast cancer samples using aCGH copy
number states as a grouping variable. Table S6. List of regions and genes
whose copy number (cbs-smoothed ratio) is positively (A) or negatively
(B) correlated with the decrease in Ki67 labeling index after 2 weeks of
aromatase inhibitor (AI) therapy.
Additional file 3: Figure S2. Deconvolution of CHKA siRNA and shRNA
pools. SUM44 cells were transfected with Individual siRNA and shRNA
from various manufacturers and the impact on proliferation measured
after 6 days. CHKA knockdown was confirmed in each case by
quantitative real-time PCR.
Additional file 4: Figure S3. Copy number analysis of SUM44,
MDA-MB134-VI, T47D, MCF7 and long-term estrogen deprived (LTED) by
quantitative real-time PCR (qRT-PCR) (A) and transcript levels of CHKA in the
target cell lines used for functional analysis measured by qRT-PCR (B).
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